Testing a new treatment to protect the brain after a stroke
Official title: Comparative testing of tatCN19o for neuroprotection in rodent tMCAo
Funded at Neurexis Therapeutics, INC. · NIH-11058404 · Data updated 2026-11-12
This study is testing a new treatment called tatCN19o to see if it can help protect the brain during and after a stroke, using small doses in rodent models to find out how well it works compared to current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neurexis Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Aurora, United States) |
| Project start | April 15, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $299,550 |
| NIH project number | 5U44NS132339-03 |
| Project ID | NIH-11058404 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced a stroke or are at high risk for stroke, particularly those over 21 years old.
✕Less likely to help
Patients who have not experienced a stroke or have conditions unrelated to cerebrovascular health may not benefit from this research.
What this research studies
This research focuses on developing a new peptide treatment called tatCN19o that aims to protect the brain during and after a stroke. The study will involve testing this treatment in rodent models of stroke to evaluate its effectiveness compared to existing therapies. The approach includes administering the peptide at very low doses and observing its neuroprotective effects over time. By using advanced testing methods, the researchers hope to gather reliable data on how well tatCN19o can prevent brain damage caused by ischemia.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that significantly reduces brain damage and improves recovery outcomes for stroke patients.
How similar studies have gone: Previous research has shown promising results with similar neuroprotective approaches, indicating potential for success in this novel treatment.
Where this research is happening
-
Neurexis Therapeutics, INC.
Aurora, United States Active
Researchers
- Principal investigator: Goforth, Robyn L — Neurexis Therapeutics, INC.
- Study coordinator: Goforth, Robyn L
Related research
Other NIH-funded projects on the same topics.
-
Neuroprotective peptide therapy for global brain injury after cardiac arrest
A promising peptide drug (tatCN19o) is being prepared for human testing to protect the brain after cardiac arrest and global brain ischemia.
-
Neuroprotective peptide to help people with Alzheimer’s disease
A patient-focused study tests whether a peptide that protects brain cells during injury can also help improve memory and thinking in people impacted by Alzheimer’s disease.
-
A potential brain-protecting drug for people with brain injury after cardiac arrest
A new drug is being developed to protect the brain in people who suffer severe lack of oxygen to the brain after cardiac arrest.
-
Developing a new drug to protect the brain after cardiac arrest
This study is testing a new drug designed to help protect the brain after a cardiac arrest, and it's for people who want to see better recovery outcomes after such an event.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.